Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 15Carcinoma 5Neoplasm Metastasis 3Colonic Neoplasms 3Brain Neoplasms 3Prostatic Neoplasms 2Peritoneal Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Vipoma 1Recurrence 1Neuroendocrine Tumors 1Meningeal Carcinomatosis 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Hormone Refractory Prostate Cancer 1Head and Neck Neoplasms 1Glioblastoma 1Gastrinoma 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms, Male 1Advanced Malignancies 1

Interventions

radium Ra 223 dichloride 2gossypol acetic acid 1epothilone B 1cabazitaxel 1bafetinib 1Everolimus 1Denosumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hormone Refractory Prostate Cancer × epothilone B × Clear all
NCT00407251 2010-11-05

Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

British Columbia Cancer Agency

Phase 2 Completed
73 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡